Adeno-associated virus (AAV), valued for its low immunogenicity, broad tropism, and long-lasting in vivo gene expression, has emerged as the leading vector for gene therapy delivery.
For AAV vectors intended for clinical use, the FDA requires stringent quality control to mitigate potential risks. This involves evaluating the ratio of empty to full capsids and monitoring impurity levels. Transmission electron microscopy (TEM) is one of the most effective QC methods, offering direct visualization. Using specific staining, TEM clearly determines the full-to-empty capsid ratio, establishing itself as a standard in quality control processes.
While gradient ultracentrifugation generally produces highly purified AAV preparations, some unknown contaminants can still persist in the final product—a common issue in many commercial AAV preps. These contaminants often manifest as small complexes or particles that are difficult to eliminate through standard purification techniques (Figure 1). Their presence can be particularly problematic for downstream research, as they have the potential to interfere with experimental outcomes, reduce the efficacy of the AAV vectors, and introduce variability in results.

What were these particles? And where did they originate?
Researchers and manufacturers must remain vigilant in identifying and addressing these impurities to ensure the integrity and reliability of AAV-based research and applications. Ongoing improvements in purification processes and more stringent quality control measures are essential to mitigate the impact of these contaminants and enhance the overall success of AAV-based therapies and experiments.
We, at PackGene, a reputable provider of AAV services and solutions, consistently uphold the highest industry standards for AAV production and quality testing. Not only were we curious about these findings, but we also wanted to understand the substance and eliminate any impurities from a quality assurance perspective. As a result, this observation prompted a thorough investigation, and we decided to conduct further testing on the samples.
Silver staining of SDS-PAGE gels from these samples revealed distinct contaminated protein bands, which were clearly clustered around the 20 kDa range, as shown in Figure 2. This finding prompted further investigation, and subsequent analysis indicated that these bands corresponded to the same contaminant particles observed in the TEM images.




Conclusion:
Since identifying ferritin contamination, we have implemented an optimized purification process across all our standard AAV production. This enhancement further ensures the superior quality and purity of PackGene’s AAV products, reinforcing our commitment to delivering reliable solutions for advanced research and therapeutic applications.
1.Sean M. Crosson, Peter Dib, J. Kennon Smith, Sergei Zolotukhin,
Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation,Molecular Therapy – Methods & Clinical Development,Volume 10,2018,Pages 1-7
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE